Axsome Therapeutics, Inc.

NasdaqGM:AXSM Stock Report

Market Cap: US$4.0b

Axsome Therapeutics Past Earnings Performance

Past criteria checks 0/6

Axsome Therapeutics's earnings have been declining at an average annual rate of -29.5%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 79.1% per year.

Key information

-29.5%

Earnings growth rate

-22.8%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate79.1%
Return on equity-334.7%
Net Margin-91.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Axsome Therapeutics Remains A Buy Despite AXS-05's Mixed Results

Dec 31

Investors Still Waiting For A Pull Back In Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Dec 23
Investors Still Waiting For A Pull Back In Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Axsome: Focus On AXS-12 Targeting Narcolepsy, Which Just Released Positive Data

Nov 29

Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?

Nov 25
Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?

Axsome Therapeutics Q3 Earnings: Stay For The Near Term Catalysts, Then Sell

Nov 12

Axsome: AXS-07 And Its Upcoming Second PDUFA

Oct 15

Getting In Cheap On Axsome Therapeutics, Inc. (NASDAQ:AXSM) Might Be Difficult

Sep 06
Getting In Cheap On Axsome Therapeutics, Inc. (NASDAQ:AXSM) Might Be Difficult

Axsome's Auvelity: High Hopes Meet Hefty Bills (Rating Downgrade)

Aug 06

Axsome Therapeutics: Lots Of Moving Parts

Jul 23

Health Check: How Prudently Does Axsome Therapeutics (NASDAQ:AXSM) Use Debt?

Jul 02
Health Check: How Prudently Does Axsome Therapeutics (NASDAQ:AXSM) Use Debt?

Why Axsome Therapeutics Is A Promising Stock Pick In CNS Treatments

May 10

Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 09
Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues

Apr 13
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues

Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?

Mar 17
Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?

Axsome: Unpacking Auvelity's First-Year Market Dynamics And Economic Challenges

Feb 21

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) P/S Is Still On The Mark Following 27% Share Price Bounce

Dec 27
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) P/S Is Still On The Mark Following 27% Share Price Bounce

Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?

Dec 12
Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?

Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?

Sep 12
Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues

Aug 08
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues

Upgrade: Analysts Just Made A Dazzling Increase To Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Forecasts

May 13
Upgrade: Analysts Just Made A Dazzling Increase To Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Forecasts

Earnings Update: Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Mar 03
Earnings Update: Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt Sensibly?

Mar 01
Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt Sensibly?

Is Axsome Therapeutics (NASDAQ:AXSM) Weighed On By Its Debt Load?

Nov 14
Is Axsome Therapeutics (NASDAQ:AXSM) Weighed On By Its Debt Load?

Axsome Therapeutics: Clear Path Ahead For AXS07

Oct 05

Axsome to resubmit marketing application for migraine therapy in Q3 2023

Sep 29

Axsome: In The Middle Of Uncertainty Is Your Biggest Opportunity

Sep 16

Axsome begins enrolling in late-stage study of migraine drug AXS-07

Sep 01

Axsome gains 19% as FDA approves depression therapy

Aug 19

Axsome Therapeutics Q2 2022 Earnings Preview

Aug 08

Axsome: Breaking Bearish Trend

Jul 26

Axsome: One Step At A Time

Jul 01

Revenue & Expenses Breakdown

How Axsome Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:AXSM Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24338-311385163
30 Jun 24291-309373146
31 Mar 24251-296348117
31 Dec 23271-23932398
30 Sep 23223-20229882
30 Jun 23182-18425668
31 Mar 23145-15920863
31 Dec 2250-18715958
30 Sep 2226-16011757
30 Jun 229-1509655
31 Mar 220-1418154
31 Dec 210-1306758
30 Sep 210-1265862
30 Jun 210-1144463
31 Mar 210-1003559
31 Dec 200-1032970
30 Sep 200-992462
30 Jun 200-952163
31 Mar 200-901663
31 Dec 190-681454
30 Sep 190-531141
30 Jun 190-421032
31 Mar 190-371026
31 Dec 180-31923
30 Sep 180-29921
30 Jun 180-27919
31 Mar 180-26819
31 Dec 170-29720
30 Sep 170-29721
30 Jun 170-30722
31 Mar 170-29722
31 Dec 160-27621
30 Sep 160-23518
30 Jun 160-21414
31 Mar 160-16310
31 Dec 150-1227
30 Sep 150-1026
30 Jun 150-626
31 Mar 150-625

Quality Earnings: AXSM is currently unprofitable.

Growing Profit Margin: AXSM is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: AXSM is unprofitable, and losses have increased over the past 5 years at a rate of 29.5% per year.

Accelerating Growth: Unable to compare AXSM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AXSM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (42%).


Return on Equity

High ROE: AXSM has a negative Return on Equity (-334.73%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 07:01
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Axsome Therapeutics, Inc. is covered by 26 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Esther Lannie HongBerenberg
Jason Matthew GerberryBofA Global Research